U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. News & Events for Human Drugs
  4. 2022 FDA/DIA Oligonucleotide-based Therapeutics Conference - 04/25/2022
  1. News & Events for Human Drugs

Conference | Mixed

Event Title
2022 FDA/DIA Oligonucleotide-based Therapeutics Conference
April 25 - 27, 2022

Date:
April 25 - 27, 2022
Day1:
Mon, Apr 25
Day2:
Tue, Apr 26
Day3:
Wed, Apr 27
Location:
Event Location
Bethesda North Marriott
Hotel & Conference Center

5701 Marinelli Road
Rockville, MD 20852
United States


Goals and Objectives:

  • Provide a forum for open discussion between industry, academic, and government scientists regarding challenges and experiences encountered in oligonucleotide drug development.
  • Seek feedback from industry, academia, and other stakeholders on the current progress and challenges in oligonucleotide research and drug development.
  • Assess the impact of regulations and guidance on oligonucleotide drug development and discuss possible avenues for changes and improvements.
  • Facilitate open discussions among all industry researchers and regulatory agencies regarding oligonucleotide drug development.

Who Should Attend:

The 2022 DIA/FDA Oligonucleotide-based Therapeutics Conference is intended for a diverse group of scientists responsible for the evaluation of safety and efficacy of oligonucleotide products including interested industry, academic and government parties involved in ongoing efforts in the research and development of oligonucleotides.

The primary audience includes leading academic experts, interested pharmaceutical companies, regulatory agencies, patient advocacy groups, non-profit organizations, scientists, clinicians from regulatory, academic, industrial and other healthcare sectors, scientists involved in drug development in those same industries, regulatory scientists, experts and leaders from industry, academia, regulatory government agencies in the US and abroad, patient representatives, healthcare providers, and pharmacokineticists (clinical, preclinical, and toxicokinetics) who are involved in oligonucleotide drug development or supporting research. 

Conference website

Contact

If to DIA: 

Robin M. Weinick, Senior Vice President and Managing Director, Americas
Global Program Officer
Drug Information Association (DIA)
800 Enterprise Road, Suite 200
Horsham, PA 19044-3595
CustomerService@DIAglobal.org
1-888-257-6457

If to FDA:     

Ronald Wange, Ph.D.
Associate Director for Pharmacology and Toxicology
FDA/CDER/OMPT/OND
Bldg 22, Room 3342
Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
Ronald.Wange@fda.hhs.gov

Back to Top